Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Highlight Therapeutics Announces Second Collaboration with MSD to Evaluate Combination of BO-112 and Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics & Pivotal Advance into a Phase IIa Trial to Examine Gastro-Intestinal Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight & Pivotal start Phase IIA Melanoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics To Present Phase 2 Data at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Highlight Therapeutics

    Menu

    Highlight Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Highlight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

              Details:

              BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn 'cold' tumors 'hot' and therefore visible to the immune system.

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Highlight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Highlight Therapeutics To Present Phase 2 Data at AACR

              Details:

              Presentation will cover Phase IIa open-label clinical study of intratumoral administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer.

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 14, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Highlight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Highlight & Pivotal start Phase IIA Melanoma Trial

              Details:

              Trial will examine administration of Highlight's BO-112 in combination with an anti-PD1 in unresectable or metastatic melanoma patients.

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Highlight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Highlight Therapeutics & Pivotal Advance into a Phase IIa Trial to Examine Gastro-Intestinal Cancer Therapy

              Details:

              First cohort of patients has been recruited in a Phase IIa study to assess Highlight’s lead program BO-112 in combination with an anti-PD1 therapy, in patients with liver metastasis from colorectal or gastric/gastro-esophageal junction cancers.

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Pivotal

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Highlight Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Highlight Therapeutics Announces Second Collaboration with MSD to Evaluate Combination of BO-112 and Keytruda®

              Details:

              The collaboration will focus on the Phase II evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients that have progressed on anti-PD-1- based therapy in refractory advanced malignant melanoma.

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Recipient: Merck & Co

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Highlight Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis

              Details:

              Highlight Therapeutics dosed first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY